Edition:
United Kingdom

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

8,284.00ILa
16 Aug 2018
Change (% chg)

218.00 (+2.70%)
Prev Close
8,066.00
Open
8,280.00
Day's High
8,289.00
Day's Low
8,250.00
Volume
141,358
Avg. Vol
633,686
52-wk High
9,111.00
52-wk Low
3,820.00

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 1.24
Market Cap(Mil.): ₪65,841.12
Shares Outstanding(Mil.): 1,014.36
Dividend: 30.51
Yield (%): 6.31

Financials

  TEVA.TA Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -21.22 -- --
ROI: -10.61 15.07 14.61
ROE: -24.14 16.59 16.33

Teva Pharma shares sink as sales forecast disappoints market

TEL AVIV Teva Pharmaceutical Industries on Thursday raised its profit outlook for 2018 after reporting a smaller than expected drop in second-quarter net profit, but its shares tumbled eight percent on disappointment over its unchanged revenue outlook.

02 Aug 2018

Teva Pharm shares sink as sales forecast disappoints market

TEL AVIV Teva Pharmaceutical Industries on Thursday raised its profit outlook for 2018 after reporting a smaller than expected drop in second-quarter net profit, but its shares tumbled eight percent on disappointment over its unchanged revenue outlook.

02 Aug 2018

UPDATE 3-Teva Pharm shares sink as sales forecast disappoints market

* Company still sees FDA approval of migraine drug mid-September

02 Aug 2018

Teva Pharm Q2 profit beats estimates, raised full year outlook

TEL AVIV, Aug 2 Israel's heavily indebted Teva Pharmaceutical Industries reported a smaller than-expected drop in second-quarter profit on Thursday and raised its profit outlook for the full year.

02 Aug 2018

Teva hopes to launch migraine drug as soon as September

JERUSALEM Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.

23 May 2018

UPDATE 1-Teva hopes to launch migraine drug as soon as September

JERUSALEM, May 23 Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.

23 May 2018

Teva Pharm says FDA to decide on migraine drug on Sept 16

JERUSALEM, May 23 Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.

23 May 2018

BRIEF-Teva Confirms September PDUFA Date For Fremanezumab

* TEVA PHARMACEUTICAL INDUSTRIES LTD - PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR FREMANEZUMAB IS SET FOR SEPTEMBER 16

23 May 2018

Berkshire Hathaway doubles Teva bet, confirms Apple purchases

May 15 Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest shareholder.

15 May 2018

BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion

* TEVA CANADA ANNOUNCES THE LAUNCH OF TEVA-CYCLOSPORINE® OPHTHALMIC EMULSION, THE FIRST GENERIC VERSION OF RESTASIS® IN CANADA FOR THE TREATMENT OF DRY EYE DISEASE

10 May 2018

Earnings vs. Estimates